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Bronchiectasis is a type of chronic obstructive pulmonary disease, defined as permanent abnormal dilation of bronchi due to vicious cycle of transmural 
infection and inflammation. Bronchiectasis is generally characterized by cough, wheeze, and dyspnea. Pathogens responsible for bronchiectasis 
include pathogens Haemophilus influenzae, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, and nontuberculous 
mycobacteria. Empirical antibiotic therapy and other drugs are used empirically in the management of bronchiectasis.Here, we discuss a case of 
infectious exacerbation of bronchiectasis successfully treated with an empirical use of ceftriaxone/sulbactam/disodium edetate-1034.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized 
by airflow limitation [1]. COPD is the fifth major cause of global 
mortality [1]. Bronchiectasis is a type of COPD, defined as 
permanent abnormal dilation of bronchi due to vicious cycle 
of transmural infection and inflammation [2]. Bronchiectasis is 
generally characterized by cough, wheeze, and dyspnea [3]. COPD 
and bronchiectasis are major cause of mortality and may be life 
threatening if not treated timely [2]. In bronchiectasis, internal 
bronchial diameter is more than adjacent pulmonary artery and 
thickening of the bronchial wall [3]. An American study reported 
52 cases of bronchiectasis per 100,000 subjects [4]. In a German 
study, 40% of bronchiectasis-associated deaths occurred in hospital. 
This study reported an increase in hospitalization at rate of 2.9% 
per year [5]. In a British Thoracic Society, audit in 2011, annual 
exacerbation rate in bronchiectasis patients found to be 2.6% [6]. 
Bronchiectasis leads to prolonged hospitalization [3,6]. Identification 
of exacerbation is more complex in bronchiectasis. In a retrospective 
study on 100 bronchiectasis patients, Bopaka et al. in 2015, found 
35% cases with microbial pathogens [7]. The reason for the lower 
prevalence of bacterial pathogens may be because sampling in 60% 
cases was done after initiation of antibiotic therapy [7].
Pathogens responsible for bronchiectasis include pathogens 
Haemophilus influenzae, Pseudomonas aeruginosa, Streptococcus 
pneumoniae, Staphylococcus aureus, and nontuberculous 
mycobacteria [7-9]. Empirical antibiotic therapy and other drugs 
are used empirically in the management of bronchiectasis [6]. Early 
initiation of antibiotics in acute exacerbation of bronchiectasis will be 
beneficial in the management of disease [3,10].
Increased resistance of pathogens toward antibiotics leads to demand 
for newer antibiotics. Elores is a novel antibiotic adjuvant entity 
consisting of ceftriaxone, sulbactam and disodium edetate (EDTA) 
which has shown broad-spectrum activity in lower respiratory tract 
infections [11].
We present a case of infectious exacerbation of bronchiectasis 
successfully treated with ceftriaxone/sulbactam/disodium edetate 
(CSE-1034), an antibiotic adjuvant entity.
CASE REPORT
A 70-year-old male patient was admitted to hospital in ICU with 
complaints of dyspnea, cough with expectoration and fever. The patient 
had history of pulmonary tuberculosis and was on anti-tubercular 
treatment. On examination, patient’s vitals were blood pressure 
of 140/90 mmHg, pulse rate: 120/minute, SPO2: 80%.
Systemic examination revealed cardiovascular system: Normal S1 S2, 
per abdomen soft and nontender, central nervous system: Conscious and 
oriented. Chest examination showed decreased air entry on right side. 
Jugular vein pressure was increased. Physical examination revealed pedal 
edema. Biochemical parameters were total bilirubin 17 mg/dl, direct 
bilirubin 0.12 mg/dl, indirect bilirubin 16.88 mg/dl, SGOT 24.87 U/l, 
SGPT 14.48 U/l, Alkaline phosphatase 44.59 U/l, Total serum proteins 
4.89 g/dl, serum albumin 2.71 g/dl, serum globulin 2.18 g/dl, Urea 
15.46 mg/dl, serum creatinine 0.94 mg/dl. X-ray examination showed 
right-sided pleural effusion with bilateral pneumonia. The patient had 
received levofloxacin and piperacillin+tazobactam at private hospital for 
a duration of 5 days. Thus based on clinical, hematological, biochemical, 
and radiological examination patient was diagnosed of infectious 
exacerbation of bronchiectasis.
Patient was empirically given CSE-1034 (Elores™) 1.5 g iv twice a day 
via iv infusion for 90 minutes. Patient was conservatively managed and 
supportive treatment (nebulization with formamide, prednisone 10 mg q 
24 hrs orally, esomeprazole 400 mg + domeperidone 30 mg q 12 hrs orally, 
tamsulosin 0.2 mg q 24 hrs orally, aspirin 75 mg + rosuvastatin 75 mg + 
clopidogrel 75 mg q 24 hourly, etizolam 0.5 mg + escitalopram 10 mg q 24 
hrs at bed time) was given. Biochemical parameters on fourth day were 
total bilirubin: 0.16 mg/dl, direct bilirubin: 0.07 mg/dl, indirect bilirubin: 
0.09 mg/dl, SGOT: 18.28 U/l, SGPT: 16.04 U/l, alkaline phosphatase: 
49.28 U/l, total serum proteins: 5.59 g/dl, serum albumin: 3.22 g/dl, serum 
globulin: 2.37 g/dl, urea: 18.96 mg/dl, serum creatinine: 0.87 mg/dl.
On fifth day, patient had symptomatic relief except dyspnea and had 
no fever, no chest pain, and no cough. Patient continued on same 
medications.
On ninth day, patient complained of fever, dyspnea, and cough. Patient 
was started with Injection dexamethasone 8 mg q 12 hrs, azithromycin 
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500 mg od orally, paracetamol 500 mg q 12 hrs orally, esomeprazole 
400 mg + domperidone 30 mg q 12 hrs orally, acebrophylline 100 mg q 
12 hrs orally and nebulization with formemide, Elores™ 1.5 g q 12 hrs 
via iv infusion for 90 minutes was continued.
On 13th day, dyspnea improved and patient continued to show 
improvement in symptoms and general health. The patient was shifted 
from ICU to ward on the 13th day of admission.
On 15th day his blood pressure was 130/80 mmHg, pulse 90/minute and 
SPO2 94%. Patient was afebrile. Cardiovascular examination revealed S1 
S2 normal. Hematological parameters were hemoglobin: 12.5 g/dl, total 
leukocyte count: 7200/cumm, red blood cells count: 4.3 million/cumm, 
platelets: 347000/cumm. He had normal renal function test, urea: 
18.96 mg/dl, serum creatinine: 0.87 mg/dl. Patient was clinically cured 
and discharged on 15th day of admission. Fig. 1 showed schematic 
representation of clinical picture of patient.
DISCUSSION
Bronchiectasis may require extensive medical care and 
hospitalization [12]. The aim of treatment for bronchiectasis is to 
improve the quality of life, eradicate the bacterial pathogen, and 
symptomatic relief.
The current report presents a case of 70-year-old male patient suffering 
from acute infectious exacerbation of bronchiectasis.
Patient empirically started, with CSE-1034 (Elores™) 1.5 g q 12 hrs 
via IV infusion for 12 hrs. Guidelines and literature recommended 
early use of empirical antibiotic therapy for management of 
exacerbation of bronchiectasis [3]. CSE-1034 was selected as 
empirical therapy in this case. In a large number of cases of LRTI, 
no pathogen was found because of inappropriate techniques or the 
pathogen was missed [13]. Elores™ is antibiotic adjuvant entity 
very effective in MDR, extended-spectrum-beta-lactamases (ESBL) 
and metallo beta-lactamase (MBL) pathogens [11]. CSE-1034 
(ceftriaxone/sulbactam/disodium edetate) was empirically selected 
for treatment of bronchiectasis because of its established safety, 
efficacy and broad spectrum activity against ESBL/MBL producing 
pathogens in LRTI [11].
Antibiotic resistance is one of the major reasons for failure of 
antibiotic therapy. Antibiotic resistance is increasing in pathogens 
like Acinetobacter baumannii, H. influenza P. aeruginosa, Klebsiella 
pneumoniae, Klebsiella oxytoca, S. aureus [11]. These pathogens 
develop resistance to antibiotic mainly by overexpression of efflux 
pump, biofilm formation, production of ESBLs and MBLs and change 
in membrane permeability [11,14-16]. Use of disodium edetate along 
with ceftriaxone and sulbactam i.e., CSE-1034, drastically reduces 
antibiotic resistance by acting on different antibiotic resistance 
mechanisms, i.e., by downregulating the efflux pump, destruction of 
biofilms by increasing porosity, inhibiting MBL activity by chelation 
of zinc ions, enhancing penetration of ceftriaxone sulbactam through 
bacterial cell [15-19].
A randomized, multi-centered phase 3 study on 93 subjects with LRTI, 
Elores showed significantly better clinical cure rates as compared to 
ceftriaxone [11].
A study conducted on 663 clinical isolates (from sputum, blood, urine, 
and pus), showed overall prevalence of ESBL 82.5%. The clinical 
isolated detected were P. aeruginosa (89 %) Escherichia coli (85.3%), 
K. pneumoniae (76.6%), K. oxytoca (73.0%), A. baumannii (72.2%) 
and S. aureus (31.2%). Susceptibility of CSE-1034 against these ESBL 
producing isolates was 95.7 % with minimum inhibitory concentration 
of 0.125-8 mcg/ml. Whereas susceptibilities were <45 % against all 
isolates with piperacillin and tazobactam, amoxicillin and clavulanic 
acid, cefoperazone and sulbactam [20].
As the patient had previously received levofloxacin and 
piperacillin+tazobactam, and patient did not respond to given antibiotics 
so these antibiotic were not continued as empirical therapy [5,10]. 
As use of intravenous antibiotics is recommended, initially so CSE-1034 
was given via iv infusion [5].
Fig. 1: Schematic representation of clinical course for management of hospital acquired pneumonia in a 70-year-old patient
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Prednisolone 10 mg q 24 hrs orally helps in the management of COPD. 
Moreover, studies reported reduced duration of hospitalization in COPD 
by using low dose of oral corticosteroids [21].
Patient was provided with other supportive medicines (esomeprazole 
400 mg + domeperidone 30 mg q 12 hrs orally, tamsulosin 0.2 mg q 
24 hrs orally, aspirin 75 mg +rosuvastatin 75 mg + clopidogrel 75 mg q 
24 hourly, etizolam 0.5 mg + escitalopram 10 mg q 24 hrs at bed time.] 
for effective management of disease.
Patient responded well to the empirical therapy of Elores. Patient was 
shifted from ICU toward in 13 days with clinical improvement and relief 
in symptoms of cough and dyspnea. The patient was discharged after 
clinical cure with the use of CSE-1034 on the 15th day with normal TLC 
count, normal body temperature. This case suggests that CSE-1034 can 
be a valuable drug to treat infectious exacerbation of bronchiectasis.
CONCLUSION
New Antibiotic Adjuvant Entity, i.e., CSE-1034 may be a preferred choice 
as empirical therapy in acute infection of exacerbation in bronchiectasis 
which may be caused by ESBL producing Gram-negative pathogens, or 
MDR bugs. Along with aggressive supportive management treatment. 
Hence, Elores™ can be a safer alternative and may be used as initial 
broad spectrum antibiotic to cover probable MDR pathogens for the 
management of exacerbation in bronchiectasis.
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